Published in J Alzheimers Dis on December 01, 2004
A Multicenter Study of NAP (AL-108) in Schizophrenia (AL-108) | NCT00505765
Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov (2009) 2.08
Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease. J Cell Mol Med (2008) 1.48
Neuroprotection by endogenous and exogenous PACAP following stroke. Regul Pept (2006) 1.12
Strategies for diminishing katanin-based loss of microtubules in tauopathic neurodegenerative diseases. Hum Mol Genet (2010) 1.03
Tau-targeted treatment strategies in Alzheimer's disease. Br J Pharmacol (2012) 1.03
Soluble forms of tau are toxic in Alzheimer's disease. Transl Neurosci (2012) 1.02
Current therapeutic targets for the treatment of Alzheimer's disease. Expert Rev Neurother (2010) 0.99
A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions. Mol Cell Neurosci (2010) 0.98
Activity-dependent neuroprotective protein-derived peptide, NAP, preventing alcohol-induced apoptosis in fetal brain of C57BL/6 mouse. Neuroscience (2008) 0.94
Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy. Neuropsychiatr Dis Treat (2012) 0.90
Mitochondrial abnormalities in Alzheimer's disease: possible targets for therapeutic intervention. Adv Pharmacol (2012) 0.89
Tau as a therapeutic target for Alzheimer's disease. Curr Alzheimer Res (2011) 0.89
The neuroprotective peptide NAP does not directly affect polymerization or dynamics of reconstituted neural microtubules. J Alzheimers Dis (2010) 0.86
NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42). BMC Neurosci (2008) 0.86
Tau and caspase 3 as targets for neuroprotection. Int J Alzheimers Dis (2012) 0.86
Expression of activity-dependent neuroprotective protein in the immune system: possible functions and relevance to multiple sclerosis. Neuroimmunomodulation (2009) 0.86
New horizons in schizophrenia treatment: autophagy protection is coupled with behavioral improvements in a mouse model of schizophrenia. Autophagy (2014) 0.81
Intranasal NAP (davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing α-synuclein. Pharmacol Res Perspect (2014) 0.80
NAP protects against cyanide-related microtubule destruction. J Neural Transm (Vienna) (2009) 0.80
Anti-Inflammatory Properties of NAP in Acute Toxoplasma Gondii-Induced Ileitis in Mice. Eur J Microbiol Immunol (Bp) (2015) 0.77
ADNP: in search for molecular mechanisms and innovative therapeutic strategies for frontotemporal degeneration. Front Aging Neurosci (2015) 0.77
Inhibition of glycogen synthase kinase-3 by BTA-EG4 reduces tau abnormalities in an organotypic brain slice culture model of Alzheimer's disease. Sci Rep (2017) 0.75
NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell. Curr Alzheimer Res (2007) 0.91
NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42). BMC Neurosci (2008) 0.86
Tubulin is the target binding site for NAP-related peptides: ADNF-9, D-NAP, and D-SAL. J Mol Neurosci (2006) 0.81